(Q44019734)

English

Potency and antimicrobial spectrum update for piperacillin/tazobactam (2000): emphasis on its activity against resistant organism populations and generally untested species causing community-acquired respiratory tract infections

scientific article published in May 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Potency and antimicrobial spectrum update for piperacillin/tazobactam (2000): emphasis on its activity against resistant organism populations and generally untested species causing community-acquired respiratory tract infections (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

piperacillin/tazobactam

1 reference

based on heuristic

inferred from title

3

object named as

Ronald N Jones

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

author name string

David M Johnson

1

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Douglas J Biedenbach

2

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

publication date

1 May 2002

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Diagnostic Microbiology and Infectious Disease

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

43

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

49-60

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

National survey of the in vitro spectrum of piperacillin-tazobactam tested against more than 40,000 aerobic clinical isolates from 236 medical centers.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900358-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Susceptibility of Haemophilus influenzae to piperacillin-tazobactam combinations: interpretive criteria and quality control limits for standardized tests

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900358-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900358-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of ventilator-associated pneumonia with piperacillin-tazobactam/amikacin versus ceftazidime/amikacin: a multicenter, randomized controlled trial. VAP Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900358-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative activities of piperacillin and tazobactam against clinical isolates of Legionella spp.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900358-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Tre

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900358-9

7 January 2021

based on heuristic

inferred from DOI database lookup

In-vitro activity of piperacillin/tazobactam relative to other antibiotics against blood culture isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900358-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900358-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized multicenter trial of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of severe intra-abdominal infections. Swedish Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900358-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900358-9

7 January 2021

based on heuristic

inferred from DOI database lookup

1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900358-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900358-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Macrolide and fluoroquinolone (levofloxacin) resistances among Streptococcus pneumoniae strains: significant trends from the SENTRY Antimicrobial Surveillance Program (North America, 1997-1999).

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900358-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Piperacillin/tazobactam (YTR 830) combination. Comparative antimicrobial activity against 5889 recent aerobic clinical isolates and 60 Bacteroides fragilis group strains

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900358-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Prediction of piperacillin-tazobactam susceptibility among Enterobacteriaceae, Pseudomonas aeruginosa, and other bacteria using ticarcillin-clavulanic acid, ceftazidime, and other broad-spectrum antimicrobial in vitro test results

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900358-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin for the treatment of patients with nosocomial lower respiratory tract infection. Piperacillin/tazobactam Nosocomial Pneumonia Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900358-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Antimicrobial susceptibility of blood culture isolates of viridans streptococci: relationship to a change in empirical antibiotic therapy in febrile neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900358-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetic and pharmacodynamic profile of high dose extended interval piperacillin-tazobactam

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900358-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety profile of piperacillin/tazobactam in phase I and III clinical studies

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900358-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative antimicrobial activity of piperacillin-tazobactam tested against more than 5000 recent clinical isolates from five medical centers. A reevaluation after five years.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900358-9

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro activity of piperacillin/tazobactam versus other broad-spectrum antibiotics against nosocomial gram-negative pathogens isolated from burn patients

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900358-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy, safety and tolerance of parenteral piperacillin/tazobactam in the treatment of patients with lower respiratory tract infections

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900358-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Multicenter evaluation of the in vitro activity of piperacillin-tazobactam compared with eleven selected beta-lactam antibiotics and ciprofloxacin against more than 42,000 aerobic gram-positive and gram-negative bacteria. In Vitro Susceptibility Sur

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900358-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900358-9

7 January 2021

based on heuristic

inferred from DOI database lookup

MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Americas: resistance implications in the treatment of serious infections. MYSTIC Study Group (Americas)

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900358-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of hospitalized patients with complicated skin and skin structure infections: double-blind, randomized, multicenter study of piperacillin-tazobactam versus ticarcillin-clavulanate. The Piperacillin/Tazobactam Skin and Skin Structure Study

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900358-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapy of soft tissue infections with piperacillin/tazobactam

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900358-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The efficacy and safety of piperacillin/tazobactam in the therapy of bacteraemia

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2802%2900358-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0732-8893(02)00358-9

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44019734&oldid=2105695554"